Tag:
Targacept
Latest Headlines
Latest Headlines
AstraZeneca severs ties to Alzheimer's drug from troubled Targacept
AstraZeneca has further culled the ranks of its experimental CNS meds. The London-based drug giant cut ties with two programs from its U.S. partner Targacept, including one compound in mid-stage development for mild to moderate cases of Alzheimer's disease, while gaining unfettered development options for a group of other Targacept candidates.
Targacept taps Stephen A. Hill to serve as president and CEO
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Troubled Targacept whacks laboratory ops in latest restructuring
A string of setbacks in the clinic and on the business front has forced troubled Targacept to once again take out the budget ax. This time management aimed at the company's laboratory as execs cut back on the burn yet again to help conserve a considerable cache of cash.
Targacept sharpens well-used budget ax after another drug flames out
A very bad year for Targacept just got worse. The biotech announced this morning that a mid-stage study of its program for attention deficit/hyperactivity disorder--ADHD--failed to achieve statistical significance.
Targacept CEO exits after pipeline failures
The company announced deBethizy's departure on Monday, saying that Chairman Mark Skaletsky and a trio of Targacept executives have been tapped to lead operations during the board's hunt for a new CEO.
AstraZeneca's new iMed R&D team forges first pact with Axerion
AstraZeneca's newly hatched iMed unit is in business.
Targacept slashes staff by half in wake of PhIII disaster
The late-stage collapse of Targacept's depression drug--TC-5214--will cost the jobs of close to half of the biotech's staffers, with 65 workers getting pink slips today.
UPDATED: AstraZeneca pays $50M to partner up on Amgen antibodies
AstraZeneca and Amgen struck a collaboration deal today designed to strengthen each company where it needed help the most.
Targacept scuttles diabetes drug program in fresh setback
A beleaguered Targacept took one step forward and two steps back today, killing a development program for TC-6987.
Depression drug research goes off the rails (again)
Why do drugmakers have so much trouble developing new depression treatments?
